CARxALL
The CARxALL clinical study will evaluate, for the first time, the CART CD1a (OC-1) therapy. This treatment specifically targets a subtype of T-cell leukaemia, cortical T-cell acute lymphoblastic leukaemia (coT-ALL), which accounts for 30-40% of T-ALLs and has a poor prognosis in patients who do not respond to currently available treatments.
The CARxALL trial will include both paediatric and adult patients who do not have any therapeutic alternative. Although the treatment of the patients will be carried out in Barcelona, patients from all over the world may be included in the trial.
The study has been designed with input from AEMPS and clinical experts in CAR T therapies and T-ALL.
For further information visit:
CARxALL trial